Bob Ehlers, a 62-year-old diagnosed with Alzheimer’s disease four years ago, has found renewed purpose and hope through his participation in a clinical trial at Banner Alzheimer’s Institute. Ehlers, who experienced initial memory difficulties while working as a vice president, enrolled in the Clarity AD trial to evaluate an investigational drug for memory loss, seeking alternatives to slow the disease's progression.
Empowering Through Clinical Trials
Ehlers emphasized the advantages of participating in clinical trials, noting that they provide access to state-of-the-art treatments and comprehensive support. The Clarity AD trial, for instance, arranged transportation via Lyft and provided meals during treatment visits. "Taking part in a clinical trial has felt encouraging, and my experience has been terrific," Ehlers stated.
Contribution to Lecanemab Approval
A significant highlight for Ehlers was the FDA approval of lecanemab, a drug he participated in testing. "The drug was approved based on the tests I participated in," he proudly shared, underscoring the direct impact of his involvement in research. Lecanemab represents a significant advancement in Alzheimer's treatment, offering a disease-modifying approach.
Advocacy and Support
Beyond his participation in clinical trials, Ehlers is actively involved in advocacy and volunteer work. He serves on the Banner Alzheimer’s Early-Stage Advisory Council, providing input on programs to support individuals with memory loss. Additionally, he volunteers for SCORE, assisting entrepreneurs, and launched Conexo Casa, a nonprofit aimed at improving internet accessibility for people with neuro-cognitive disorders. Ehlers believes in setting "lofty goals" to remain engaged and socially active, stimulating brain function.
Maintaining an Active Lifestyle
Ehlers maintains an active lifestyle, enjoying camping trips with his wife and cherishing time with his family. He emphasizes the importance of staying engaged and social to combat the effects of Alzheimer's. His experience highlights the potential for individuals with Alzheimer's to contribute meaningfully to research and their communities while finding personal fulfillment.
